Subscribe To
Y-mabs to announce third quarter 2023 financial and operating results on november 13, 2023
NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: ...
October 31, 2023, 11:05 am
Are medical stocks lagging apyx medical (apyx) this year?
Here is how Apyx Medical (APYX) and Cymabay Therapeutics Inc. (CBAY) have performed compared to their s...
October 26, 2023, 11:23 am
Cymabay therapeutics inc. (cbay) is on the move, here's why the trend could be sustainable
Cymabay Therapeutics Inc. (CBAY) made it through our "Recent Price Strength" screen and could be a grea...
October 25, 2023, 10:34 am
Shareholder alert: levi & korsinsky, llp notifies shareholders of an investigation concerning possible breaches of fiduciary duty by certain officers and directors of y-mabs therapeutics inc. (nasdaq:
NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) — Levi & Korsinsky announces that it has commenced an investigation of Y-mAbs Therapeutics Inc. (NASDAQ: ...
October 23, 2023, 9:45 pm
Why cymabay therapeutics stock rocketed nearly 8% higher today
The leading drug candidate in the biotech's pipeline scored another win. Seladelpar's existing Breakthrough Therapy Designation was expanded by the FD...
October 23, 2023, 6:16 pm
Why cymabay therapeutics stock is sinking this week
Cymabay Therapeutics stock is continuing a slide that began last week. The pullback came on the heels o...
September 21, 2023, 4:39 pm
Cymabay therapeutics to present at the cantor global healthcare conference
NEWARK, Calif., Sept. 15, 2023 (GLOBE NEWSWIRE) -- Cymabay Therapeutics, Inc. (NASDAQ: CBAY), a biophar...
September 15, 2023, 8:00 am
Cymabay announces closing of upsized $258.7 million public offering of common stock and pre-funded warrants, including full exercise of underwriters’ option to purchase additional shares
NEWARK, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) — Cymabay Therapeutics, Inc. (Nasdaq: CBAY), a clinic...
September 14, 2023, 8:57 pm
Why cymabay therapeutics stock triumphed again on tuesday
The biotech upsized its planned share issue. It's now seeking to raise gross proceeds of $225 million; previously, it was aiming for $150 million....
September 12, 2023, 5:37 pm
Cymabay announces pricing of upsized $225 million public offering of common stock and pre-funded warrants
NEWARK, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) — Cymabay Therapeutics, Inc. (Nasdaq: CBAY), a clinic...
September 12, 2023, 2:15 am
Why cymabay therapeutics stock popped again today
The biotech is going to the well for more capital. It is seeking to raise $150 million in a share-and-warrant flotation....
September 11, 2023, 6:31 pm
Cymabay: positive phase 3 data and competitive advantage established
Positive results achieved in phase 3 RESPONSE study, which used seladelpar for the treatment of patients with primary biliary cholangitis. Positive re...
September 10, 2023, 6:05 am
Cymabay (cbay) stock up on positive results from pbc study
Cymabay (CBAY) reports encouraging data from the phase III study of seladelpar in PBC patients. Stock u...
September 8, 2023, 2:17 pm
Why cymabay therapeutics stock is jumping today
Cymabay announced positive results on Thursday for its treatment for a rare liver disease. The company ...
September 8, 2023, 11:59 am
Cymabay therapeutics stock jumps as rare liver disease treatment shows positive results
Shares of Cymabay Therapeutics Inc. CBAY gained 23% premarket on Thursday after the company released po...
September 7, 2023, 8:04 am
Y-mabs therapeutics, inc. (ymab) q2 2023 earnings call transcript
Y-mAbs Therapeutics, Inc. (NASDAQ:ymab ) Q2 2023 Earnings Call Transcript August 11, 2023 9:00 AM ET Co...
August 11, 2023, 4:43 pm
Y-mabs therapeutics, inc. (ymab) reports q2 loss, tops revenue estimates
Y-mAbs Therapeutics, Inc. (ymab) came out with a quarterly loss of $0.14 per share versus the Zacks Con...
August 10, 2023, 6:16 pm
Cymabay's seladelpar: an exceptional ppar agonist candidate for pbc
Cymabay Therapeutics' primary candidate, seladelpar, shows promising results as a potential treatment f...
July 20, 2023, 6:50 am
Recent price trend in cymabay therapeutics inc. (cbay) is your friend, here's why
Cymabay Therapeutics Inc. (CBAY) could be a solid choice for shorter-term investors looking to capitali...
July 17, 2023, 10:35 am
Why shares of cymabay therapeutics are soaring friday
Cymabay is a clinical-stage biotech. The company focuses on liver diseases and other chronic diseases....
June 30, 2023, 11:50 am